Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

646
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
646
T Cell Types and Functions01:24

T Cell Types and Functions

1.4K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical development of tacrolimus-resistant regulatory T cells to enable simultaneous immunosuppression and immune regulation.

Molecular therapy. Advances·2026
Same author

Vortex-actuated pre-enrichment accelerates human regulatory T cell sorting and improves early fitness.

Molecular therapy. Advances·2026
Same author

Conventional type-1 DC density is associated with checkpoint inhibitor response across multiple types of cancer.

The Journal of clinical investigation·2026
Same author

TCR T cells targeting IgA- and IgG-expressing multiple myeloma.

Blood·2026
Same author

HLA matching or CRISPR editing of HLA class I/II enables engraftment and effective function of allogeneic human regulatory T cell therapy in a humanized mouse transplantation model.

Nature communications·2025
Same author

Defensive tolerance drives the reprogramming and dysfunction of infiltrating pathogenic B cells assuring the maintenance of tolerance.

Research square·2025
Same journal

Helios expression in naïve CD4+ T cells decreases from neonates to older adults.

Clinical and experimental immunology·2026
Same journal

Could we discuss the molecular signature of immune dysregulation?

Clinical and experimental immunology·2026
Same journal

The many faces of cytokine storm syndrome: immunopathogenic mechanisms and clinical implications for a better patient management.

Clinical and experimental immunology·2026
Same journal

PD-1 Engagement and Circulating Th17 Effector Activity During Secukinumab Treatment in Plaque Psoriasis.

Clinical and experimental immunology·2026
Same journal

Henoch-Schoenlein purpura (HSP) like lesions in IL12RB1 and IL12B defects - A multi-centric experience from India.

Clinical and experimental immunology·2026
Same journal

Case Series on the Efficacy of Daratumumab in Treating Patients with Anti-Interferon-Gamma Autoantibodies.

Clinical and experimental immunology·2026
See all related articles

Related Experiment Video

Updated: Sep 1, 2025

Generation of Human Chimeric Antigen Receptor Regulatory T Cells
10:29

Generation of Human Chimeric Antigen Receptor Regulatory T Cells

Published on: January 3, 2025

1.5K

Regulatory T-cell therapy approaches.

Oliver McCallion1, Merve Bilici1, Joanna Hester1

  • 1Translational Research Immunology Group, Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.

Clinical and Experimental Immunology
|August 12, 2022
PubMed
Summary
This summary is machine-generated.

Regulatory T cells (Tregs) show great promise for treating immune disorders. While clinical trials are advancing, challenges remain in applying Treg therapy widely outside of research settings.

Keywords:
CAR-Tregadoptive cell therapygene editingregulatory T celltolerance

More Related Videos

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes
16:26

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Published on: August 20, 2007

5.9K
Generation of Induced Regulatory T Cells from Primary Human Naïve and Memory T Cells
14:23

Generation of Induced Regulatory T Cells from Primary Human Naïve and Memory T Cells

Published on: April 16, 2012

24.3K

Related Experiment Videos

Last Updated: Sep 1, 2025

Generation of Human Chimeric Antigen Receptor Regulatory T Cells
10:29

Generation of Human Chimeric Antigen Receptor Regulatory T Cells

Published on: January 3, 2025

1.5K
Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes
16:26

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Published on: August 20, 2007

5.9K
Generation of Induced Regulatory T Cells from Primary Human Naïve and Memory T Cells
14:23

Generation of Induced Regulatory T Cells from Primary Human Naïve and Memory T Cells

Published on: April 16, 2012

24.3K

Area of Science:

  • Immunology
  • Cell Therapy
  • Clinical Translation

Background:

  • Regulatory T cells (Tregs) hold significant therapeutic potential for immunopathologies involving aberrant immune activation.
  • Adoptive transfer of ex vivo expanded autologous Tregs is advancing through clinical trials, showing promising safety and efficacy signals.

Approach:

  • This review examines the current state of Treg therapy.
  • It considers novel emergent approaches and technologies for engaging Tregs.
  • The review reflects on the necessary progress for patient delivery.

Key Points:

  • Treg therapy is progressing in clinical trials for various immune diseases.
  • Practical challenges hinder widespread application of Treg therapy.
  • Emerging technologies offer new strategies for Treg-based treatments.

Conclusions:

  • Regulatory T-cell therapy has vast potential but faces practical hurdles for broad clinical use.
  • Continued innovation in Treg engagement and delivery is crucial for patient benefit.